DocDollars

Ani Pharmaceuticals, Inc.

MN · United States · Reporting entity ID 100000971883

Total reported 2019–2025
$7.24M
#589 of 2,960 reporting companies — 0% of all reported industry payments
$4.93M in general payments across 76,640 records, plus $2.32M in research funding across 185 records.

How it breaks down

General payments $4,926,080
Research funding $2,316,741

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Ani Pharmaceuticals, Inc. reported $7.24M to US doctors and teaching hospitals from 2019 to 2025, ranking #589 of 2,960 reporting companies. 32% of that was research funding and 68% general payments such as consulting, speaking, food and travel. 76,640 general payment records and 185 research records were filed.

Common questions about Ani Pharmaceuticals, Inc.

How much has Ani Pharmaceuticals, Inc. paid US doctors?

Ani Pharmaceuticals, Inc. reported $7,242,821 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $4,926,080 in general payments, $2,316,741 in research funding.

How does Ani Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #589 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Ani Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.